OTCM
SRBT
, Last price
USD
Name
Shanrong Biotechnology Corp
Chart & performance
P/E
—
P/B
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-30.48%
Rev. 5Y
38.31%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-24k
L+43.38%
CFO
-77k
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shanrong Biotechnology Corp. primarily functions as a provider of executive consulting and project management services. The company specializes in the modernization of armored vehicles, integrating advanced digital communications into their systems. Furthermore, it furnishes critical spare parts and specialized equipment to both military and law enforcement organizations. Beyond hardware provision, its service portfolio also encompasses on-site maintenance, along with comprehensive training programs for maintenance personnel, operators, and tactical operations. Shanrong's expertise additionally extends to program oversight, business expansion initiatives, and strategic analysis within the defense, homeland security, information technology, and telecommunications industries. The entity, formerly known as Defense Solutions Holding, Inc., officially adopted its current name, Shanrong Biotechnology Corp., in September 2017. It is headquartered in Beverly Hills, California.
Key people
Gina A. Ringgold
Chief Financial Officer, Secretary, Director · since 2010
Avraham Gilat
Director
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||